Montanine is an alkaloid isolated from Rhodophiala bifida bulb with potential anti-arthritic activity. In this context, we evaluated whether montanine has a disease modifying anti-rheumatic activity in two arthritis models and its effect in vitro on lymphocyte proliferation and on invasiveness of fibroblast-like synoviocytes (FLS). Antigen-induced arthritis (AIA) was performed in Balb/C mice with methylated bovine serum albumin, and nociception and leukocytes migration into the knee joint were evaluated. Collagen-induced arthritis (CIA) was performed in DBA/1 J mice, and arthritis development and severity were assessed by clinical and histological scoring and articular nociception. Montanine was administered intraperitoneally twice a day. Lymphocyte proliferation stimulated by concanavalin A in 48 h was performed with MTT assay, while FLS invasion in 24 h was assayed in a Matrigel-coated transwell system. Administration of montanine decreased nociception (P < 0.001) and leukocyte articular migration (P < 0.001) in mice with AIA. In mice with CIA, treatment with montanine reduced severity of arthritis and joint damage assessed by clinical (P < 0.001) and histological (P < 0.05) scores and ameliorated articular nociception (P < 0.05). In vitro, montanine inhibited lymphocyte proliferation stimulated with ConA (P < 0.001) and decreased FLS invasion (P < 0.05) by 54%, with an action independent of cytotoxicity. Our findings suggest that montanine can be further explored as an innovative pharmacological approach for autoimmune diseases such as arthritis.
Introduction
Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease that affects 0.5-1% of world population and is characterized by inflammation of synovial tissue, synovial hyperplasia and development of bone and cartilage joint erosions which results in joint destruction, pain and increased risk for functional disability in RA patients (Scott et al., 2010) .
RA susceptibility and disease severity have a genetic component and different cell types and inflammatory pathways have been implicated in disease pathogenesis (Smolen and Steiner, 2003) . Early events in RA pathogenesis include the development of synovial hyperplasia, angiogenesis and synovial tissue infiltration with mononuclear cells such as T and B lymphocytes Smolen and Steiner, 2003) . The typical synovial hyperplasia, also called "pannus", consists of increased numbers of macrophage and fibroblastlike synoviocytes (FLS) (Bottini and Firestein, 2013) and is a highly invasive tissue that invades and destroys cartilage and bone Smolen and Steiner, 2003) .
Despite recent progress and significant improvement in the treatment for RA, most patients only achieve mild to moderate improvements and disease remission remains uncommon (Feldmann and Maini, 2015) . Additionally, most of the biologic therapies and small molecules are associated with increased risk for infections (Smolen et al., 2012; Feldmann and Maini, 2015) , emphasizing the need for new therapeutic strategies.
The Amaryllidaceae family has been found to be very promising as a therapeutic tool for human diseases and has been used in alternative medicine in developing countries as anti-parasitic, anti-inflammatory and anti-rheumatic agents (Louw et al., 2002; Shale et al., 1999; Agra et al., 2007; Choudhary et al., 2015) . The majority of the compounds found in Amaryllidaceae family are specific alkaloids (Louw et al., 2002) , unique to this family of plants (Viladomat et al., 1997) and appear to account for its medicinal properties. Amaryllidaceae alkaloids have been reported to have in vitro anti-inflammatory activities, inhibiting cyclooxygenase (COX)−1 (Elgorashi and van Staden, 2004) and COX-2 (Liu et al., 2015, Elgorashi and van Staden, 2004) , and reducing the release of interleukin 6 and tumor necrosis factor (TNF)-α (Kang et al., 2012) . Moreover, galantamine, the most studied Amaryllidaceae alkaloid, has a protective effect by reducing the inflammatory state of mice with lipopolysaccharide-induced endotoxemia (Pavlov et al., 2009) , high-fat diet-induced obesity (Satapathy et al., 2011) and colitis (Ji et al., 2014) and inflammation and arthritis severity in rats with adjuvant-induced arthritis (AA) (Gowayed et al., 2015) . Additionally, lycorine was found to have an antinociceptive effect in tail-flick test and reduced carrageenan-induced paw edema in rats (Çitoğlu et al., 2012) , while lycoricidinol ameliorated paw edema in rats with AA (Mikami et al., 1999) . Finally, an important characteristic of these molecules is that all Amaryllidaceae alkaloids are derived from the same basic norbelladine structure, which also has in vitro inhibitory action on COX-1 and COX-2 (Park, 2014) .
Rhodophiala bifida (Herb.) Traub is an Amaryllidaceae species native of Argentina, Uruguay and Brazil (Meerow and Snijman, 1998) . This plant has large amounts of the alkaloid montanine. Montanine has been shown to have anxiolytic, anti-depressant and anti-convulsant activities in rodents (da Silva et al., 2006) , in vitro cytotoxic activity against different human cancers cells lines (Silva et al., 2008) , and acetylcholinesterase inhibitory activity (Pagliosa et al., 2010) . The structural similarities between montanine and the others Amaryllidaceae alkaloids, and its pleiotropic pharmacologic activity raise the possibility that this alkaloid might also have anti-arthritic properties.
In the present study, we aimed to determine whether montanine has disease modifying anti-rheumatic activity such as the disease modifying anti-rheumatic drugs (DMARDs) used in RA, which would make it potentially more useful and interesting for clinical testing. For this, we evaluated the effect of montaninein two different and wellestablished models of RA, antigen-induced arthritis (AIA) and collagen-induced arthritis (CIA) and studied the impact of montanine on lymphocytes and in the regulation of FLS behaviour.
Material and methods

Plant Material
Bulbs of Rhodophiala bifida (Herb.) Traub were collected in the coast of Rio Grande do Sul, Brazil and the plant authenticity was evaluated with a voucher specimen (number 192333) deposited in the ICN Herbarium at the Universidade Federal do Rio Grande do Sul (Porto Alegre, RS, Brazil).
Extraction, purification and identification of montanine
The dried powdered bulbs of Rhodophiala bifida were macerated in sulfuric acid 2% (v/v) for four h in ultrasonic bath. Then, the sample was centrifuged at 1770g for 10 min and the supernatant was removed and filtered through vacuum in a Büchner funnel. All the supernatant obtained were mixed and then defatted with diethylether. The organic phase was discarded and the aqueous phase was basified with 20% ammonium hydroxide to pH 9-10. The basified aqueous solution was washed with ethyl acetate for three times and the organic phase was added anhydrous sodium sulfate to remove the remaining water residue. The organic solvent was separated from the solid and using a rotary evaporator and water bath at 40°C, a yellowish residue was obtained. The yellowish residue was subjected to a vacuum liquid chromatography (VLC) system, using silica gel 60 as stationary phase. Thus, hexane was added to the sample and placed to the column, being the hexane residue discarded. Next, methanol were added to the sample and also submitted to VLC. The methanol fraction was then evaporated in rotary evaporator with a water bath at 40°C until complete dryness. This dry residue was suspended in ethanol 5%, frozen and then lyophilized.
An Ultra Performance Liquid Chromatography (Waters Acquity UPLC, USA) equipped with a diode array detector (DAD) coupled with electrospray ionization in the positive ion mode (ESI(+)) quadrupole time-of-flight (Q-Tof) mass spectrometry (MS) (MS QTof MicroMicromass) was used. The separation of the compounds was performed on a C18 reverse phase column (Acquity UPLC beh, 50.0×2.1 mm, 1.7 m). The software program Mass Lynx v.4.1 was used for the analysis and data acquisition. A major peak, (at 1.13 s) was fragmented and the molecular weight observed was m/z 301.1403/302.1403 and the UV spectra of this peak was 243.9 and 291.4 nm, corresponding the alkaloid montanine, highly majoritary in the alkaloid fraction and in agreement with those reported in the literature (Wildman and Brown, 1968) . For additional confirmation, we used nuclear magnetic resonance spectroscopy with Agilent DD2 (Agilent Technologies, Santa Clara, CA, USA) with Larmor frequency of 499.726 MHz (S1 Table) , confirming the major peak as 92.5% of montanine (S1 Fig). 
Animals
Balb/C wild-type mice (male, 8-12 weeks, 20-25 g) were used for AIA and lymphocyte studies, while DBA/1 J inbred mice (male, 8-12 weeks, 18-22 g) were used for CIA and fibroblast-like synoviocytes studies. All animals were kept under a 12 h light-dark cycles, 40-60% relative humidity, temperature of 22 ± 2°C with free access to water and food. All experimental procedures were performed in strict accordance with recommendations in the National Institute of Health Guide for Care and Use of Animals and with the approval by the Committee on the Ethics of Animal Experiments of the Hospital de Clínicas de Porto Alegre (permit number: 120385). All animals were anesthetized with isoflurane (Abbott, Abbott Park, IL, USA) for arthritis induction and euthanasia and to minimize suffering, all animals were monitoring twice a week in the cage-change period to assess any behavioral change and loss of quality of life, observing the following signals: inactivity, suffering, stress, unbearable pain and no food or water intake.
Induction of AIA
AIA was performed according to (Grespan et al., 2008) . Twentyfour Balb/C mice were sensitized by subcutaneous (sc) injection with 500 μg of methylated bovine serum albumin (mBSA) (Sigma-Aldrich, Saint Louis, MO, USA) dissolved in 0.2 ml of an emulsion containing equal ratio of saline and complete Freund's adjuvant (CFA) (SigmaAldrich) administered on day 0. Booster sc injections were administered on days 7 and 14 using incomplete Freund's adjuvant (IFA) (Sigma-Aldrich). On day 21, arthritis was induced in pre-immunized animals by intra-articular (ia) injection on medial side of knee joint, between patella and femoral tibia space using a syringe and a 29 G x 1/ 2″ needle with an angle of 95 degree with the skin with 30 μg of mBSA dissolved in 10 μl of saline into the left knee joint. The contralateral joint (right joint) was injected with 10 μl of 0.9% saline alone as a negative control. Animals were divided into four groups (6 animals per group) and treatments were performed 24 h and 30 min before the ia injection of mBSA, with mice receiving montanine (0.3, 1 or 3 mg/kg) or vehicle (0.9% saline) via intraperitoneal (ip) in 100 μl. Nociception was analyzed within 24 h and mice were euthanized 24 h after arthritis induction to assess leukocyte migration to the joint. equal volumes of 2 mg/ml bovine collagen type II (CII) (Chondrex, Redmond, WA, USA) and CFA with 2 mg/ml of heat inactivated Mycobacterium tuberculosis (Strain H37 RA) (Difco Laboratories, Lawrence, KS, USA) by intradermal injection in the base of the tail on day 0. After eighteen days, a booster injection was performed in another site of the tail with 70 μl of an emulsion with CII and IFA. After booster, animals were monitored daily for clinical signs of arthritis were divided into two protocols of treatment. In the preventive protocol, 24 animals (6 per group) received montanine (0.05, 0.25 and 0.5 mg/ml) or vehicle (saline 0.9%) via ip twice a day with treatment starting on the day of booster injection and lasting for 15 days. In the therapeutic protocol, 21 animals (7 per group) received montanine (0.5 and 1.5 mg/ml) or vehicle (saline 0.9%) via ip twice a day with treatment starting on the day of arthritis onset and lasting for 10 days.
Clinical arthritis scoring of CIA
After booster injection, animals were monitored daily for clinical signs of arthritis to evaluate the development and severity of disease according to the followed standardized method (Brand et al., 2007) : 0 -normal, 1 -mild swelling and erythema, 2 -moderate swelling and erythema, 3 -severe swelling and erythema extending from the ankle to metatarsal joints, and 4 -severe erythema and swelling with loss of function. Total score of animal is the sum of the score in each paw (range: 0-16).
Evaluation of articular nociception
Articular nociception was assessed according to (Oliveira et al., 2011) ). Mice were placed in a quiet room in acrylic cages with a wiregrid floor for 15-30 min before testing for environmental adaptation. An electronic pressure meter was used (Insight Instruments, Ribeirão Preto, SP, Brazil) to automatically record the intensity of the force applied when the paw was withdrawn, with results expressed as the flexion-elicited withdrawal threshold in grams. In AIA model, nociception of the knee joint was evaluated on 0, 3, 5 and 24 h after ia injection of mBSA and in CIA model, nociception of the paw was evaluated on days 0, 2, 4, 6, 8 and 10 after onset of disease.
Evaluation of in vivo leukocyte migration in AIA
After euthanasia, the injected knee cavity of Balb/C mice were exposed by carefully cutting the patellar tendon and the synovial membrane and were washed three times with 5 μl of phosphate buffered saline (PBS) and then diluted in a final volume of 90 μl. Total leukocytes presents in PBS were diluted in Turk's solution and counted using Neubauer chamber (HBG, Giessen-Lützellinden, Germany) under optical microscopy.
Histology and histological scoring in CIA
At the end of the CIA experiment, mice were euthanized and ankle joints collected for histological analyses. Ankles were fixed in 10% buffered formalin for 7 days and then decalcified on 10% nitric acid for 24 h. Joints were embedded in paraffin and slides were prepared and stained with hematoxylin-eosin. The slides were scored by two blinded and independent investigators with a previously established score for synovial inflammation, synovial hyperplasia, extension of pannus formation, cartilage and bone erosions (Brenner et al., 2005) .
Isolation and culture of fibroblasts-like synoviocytes
The isolation and culture of FLS were performed according to (Armaka et al., 2009 ). Arthritic joints from DBA/1 J mice with CIA were collected and incubated with collagenase I (1 mg/ml) (SigmaAldrich) for 1 h at 37°C. The supernatant was collected and centrifuged at 240g for 10 m and the pellet re-suspended in Dulbecco's modified Eagle's medium high glucose (DMEM-HG) (Gibco -Thermo Fischer Scientific, Waltham, MA, USA), supplemented with 15% fetal bovine serum (FBS) (Gibco), 1% penicillin-streptomycin (Gibco) and 0.125% gentamicin, and then transferred to a 6-well plate for culture at 37°C and 5% CO 2 atmosphere. The initial culture was monitored daily until 70-80% of confluence and then cells were detached with trypsin-EDTA (Gibco) and transferred to a culture flask. FLS after five passages were used for experiments. The purity of FLS cultures was confirmed by flow cytometry (FACSCanto II) using FITC-conjugated anti-mouse cluster of differentiation (CD) 45 (Sigma-Aldrich), Alexa Fluor 647-conjugated anti-mouse CD248 (Bios Antibodies, Woburn, MA, USA) and APC-conjugated anti-mouse CD90.2 (eBioscience, San Diego, CA, USA) antibodies (Hardy et al., 2013) .
Lymphocyte viability assay
Lymphocyte viability was determined by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H tetrazolium bromide] assay (Mosmann, 1983) and was performed in two separated and independent experiments. Total lymphnodes were dissected under aseptic conditions from non-immunized Balb/C mice and lymphocytes were isolated using a 70 µm nylon mesh cell strainer (BD Biosciences). The purity of the isolations was confirmed by flow cytometry (FACSCanto II) using PerCP-Cy5.5-conjugated anti-mouse CD3 (Sigma-Aldrich) and PEconjugated anti-mouse CD19 (Sigma-Aldrich) antibodies. Cells were counted and added to a 96-well plate in triplicate at a density of 5×10 5 cells/ml. Cells were cultured in the presence or absence of montanine (0.01; 0.1; 1; 10 and 100 μM) for 24 h at 37°C in 5% CO 2 in RPMI-1640 medium (Gibco) supplemented with 10% FBS and 1% penicillin/ streptomycin. On the last 4 h, cells were incubated with 0.5 mg/ml of MTT (Sigma-Aldrich). Culture medium was then removed and 100 μl of dimethyl sulfoxide (DMSO) (Nuclear) were added to dissolve the MTT formazan crystals. Absorbance was read at 570 nm in spectrophotometer Anthos Zenyth 200rt (Biochrom, Cambridge, UK).
FLS viability assay
FLS viability was determined by MTT assay (Mosmann, 1983) and was performed in two separated and independent experiments. Semiconfluent (70-80%) cultures of FLS were harvested with trypsin-EDTA digestion and re-suspended in appropriate culture medium. Cells were added to 96-well plates at a density of 2×10 4 cells/ml. FLS were allowed to adhere over 24 h and then cultured in the presence or absence of montanine (0.01; 0.1; 1 and 10 μM) for 24 h at 37°C in 5% CO 2 . On the last 4 h, cells were incubated with MTT and the absorbance of each well measured at 570 nm in spectrophotometer.
Lymphocyte proliferation assay
Lymphocyte proliferation assay was performed as previously described (Farinon et al., 2013) in three separated and independent experiments. Lymphnodes of non-sensitized Balb/C were removed aseptically. Lymphocytes were extracted and added in triplicate at a density of 5×10 5 cells/ml in 96-well plate. Subsequently, cells were stimulated with concanavalin A (ConA) (5 μg/ml) (Sigma-Aldrich), in the presence or absence of montanine 1 μM and cultured for 48 h at 37°C in 5% CO 2 . On the last 4 h of experiment, cells were incubated with MTT and the absorbance of each well was measured at 570 nm in spectrophotometer.
FLS invasion assay
The FLS invasion assay was performed according to (Laragione et al., 2012) with minor modifications in five separated and indepen-dent experiments. 70-80% confluent FLS were harvested with trypsin-EDTA and re-suspended with serum-free DMEM-HG, placed in duplicate at a concentration of 1×10 5 cells in 500 μl in the upper compartment of the Matrigel-coated inserts in a 24-well plate transwell system (BD Biosciences). Montanine 1 μM were added to the upper compartment. DMEM-HG supplemented with 15% FBS was added to the lower compartment as a chemoattractant. Plates were cultured at 37°C in 5% CO 2 for 24 h. Non-invading cells and the Matrigel layer were removed from the upper surface of inserts with swabs and the invading cells on the lower surface stained with Crystal Violet (SigmaAldrich). The total area of inserts was photographed using a camera coupled in an inverted microscope (Olympus, Shinjuku, Tokyo, Japan) and the total number of invading cells was counted.
Statistical analysis
Sample size for AIA and CIA experiments were calculated based on previous experiments performed by our research group, assuming 95% of confidence and 80% of statistical power, using WinPEPI 11.4. Data with normal distribution are presented as mean ± S.E.M. and nonnormally distributed data are presented as median and interquartile range. Groups were compared by the one or two-way analysis of variance (ANOVA) with Bonferroni's adjustment for multiple comparisons, by Student's t-test or Mann-Whitney test using GraphPad Prism 5.0. Statistical differences were considered significant with a P value ≤0.05.
Results
Montanine reduced inflammatory parameters in mice with AIA
We first examined the effect of montanine on leukocyte influx and pain in acute AIA. Vehicle-treated mice had pronounced increased inflammation-related nociception starting at 3 h after the ia injection of mBSA further increasing at 5 and 24 h, as compared with that in the saline-injected contralateral joint of the same mice. Treatment with montanine in all doses significantly reduced nociception at 5 h (P < 0.01) and 24 h (P < 0.001), comparing with vehicle-treated mice (Fig. 1A) .
Ia injection of mBSA generated a massive recruitment of leukocytes to the knee joint cavity of vehicle-treated mice, as compared with the ia injection of saline in the contralateral joint of the same mice and treatment with montanine (all concentrations) markedly and significantly reduced the numbers of leukocytes in the knee by 90% (P < 0.001) (Fig. 1B) .
Preventive use of montanine delayed disease onset and reduced disease severity in CIA
Disease onset in the CIA mice treated with saline was typically at day 18 after the induction of disease, and all animals were affected at day 25. The peak of disease's severity was at day 32 after induction (day 14 after booster injection). All three doses of montanine administered in the preventive treatment arm (before onset of arthritis), delayed disease onset by nearly 7 days ( Fig. 2A) . Montanine doses of 0.25 and 0.5 mg/kg significantly reduced disease severity throughout the observation period while the 0.05 mg/Kg dose was only protective until day 10 after booster ( Fig. 2A) .
Montanine administered after the onset of arthritis significantly reduced disease severity
In this set of experiment, montanine treatment was started after the onset of arthritis, which mimics the clinical scenario of RA. Montanine 0.5 mg/kg significantly and persistently reduced the arthritis severity scores (Fig. 2B ) and also ameliorated paw nociception at day 2 and 10 after first clinical sign of arthritis (Fig. 2C) .
Montanine reduced histological appearance of inflammation and damage in CIA
Vehicle-treated mice had marked synovial infiltration of inflammatory cells with pannus formation and extensive cartilage and bone erosion (Fig. 3A) . On the other hand, mice treated with montanine 0.5 mg/Kg had minimal to no inflammatory cells infiltration, pannus formation or cartilage erosion in both preventive (Fig. 3B ) and therapeutic arms (Fig. 3C) . Montanine-treated mice had significantly lower histologic scores in all analyzed parameters (inflammation, hyperplasia, erosion) compared with vehicle-treated mice, further supporting the clinical results (Table 1) .
Montanine reduced in vitro lymphocyte proliferation
The lymphocytes isolated from health mice lymph nodes and used in the in vitro experiments were majority T cells (Appendix B). First, we examined the potential toxicity and cell death induced by montanine on lymphocytes using a viability assay. There was no significant toxicity or increased cell death at concentrations from 0.01 to 1 μM M. Farinon et al. European Journal of Pharmacology 799 (2017) 180-187 ( Fig. 4A) . Therefore, we used the 1 μM concentration for the in vitro proliferation assay. ConA stimulation significantly increased lymphocyte proliferation compared with non-stimulated lymphocytes, and treatment with montanine reduced this proliferation by 54% (P < 0.001) (Fig. 4B ).
Montanine reduced in vitro invasiveness of FLS
Finally, we evaluated the effect of montanine on the invasive phenotype of FLS, a key process implicated in cartilage and bone pannus invasion and articular destruction, using a commercial Matrigel-coated transwell system. The purity of the FLS cultures was confirmed by negative expression of CD45 and positive expression of CD248 and/or CD90.2 in the population by flow cytometry (Appendix C). First, we did a dose titration to determine the maximum non-toxic concentration of montanine on DBA/1 J FLS (Fig. 5A) . The selected concentration of 1 μM was used to study invasion of FLS from five different DBA/1 J with CIA. Treatment with montanine reduced FLS invasion by 54% (P < 0.05) (Fig. 5B and C) .
Discussion
Animal models of arthritis are important tools to identify potential new therapeutic agents for RA (Hegen et al., 2008) . Since there is no universal model that reflects all articular and systemic features of the human disease (Kollias et al., 2011; Hu et al., 2013) it is important to perform studies in more than one model, involving different pathogenic pathways. Antigen-induced arthritis (AIA) (Brackertz et al., 1977) generates in 24 h an acute joint inflammation characterized by swelling, polymorphonuclear infiltration and pronounced hyperalgesia (Ebbinghaus et al., 2012) . On the other hand, the development of collagen-induced arthritis (CIA) (Trentham et al., 1977 ) is dependent (C) Nociception in therapeutical treatment protocol. Montanine 0.5 mg/kg ameliorates nociception at days 2 and 10. Each bars represents mean ± S.E.M. in 7 mice per group. *P < 0.05**P < 0.01***P < 0.001 versus vehicle by two-way ANOVA followed by Bonferroni's post-hoc test. of both innate and adaptive immune responses and leads to chronic polyarthritis with joint inflammation and cartilage and bone erosion (Ferraccioli et al., 2010) . In addition, it is important to evaluate the effect of a potential new therapeutic agent on phenotypes of cells involved in the pathogenesis of the disease, such as the invasiveness of FLS and the exacerbated proliferation of lymphocytes. Based on that, in the present study, we evaluated the effect of montanine, an alkaloid isolated from Rhodophiala bifida bulbs, on these two different models of arthritis. Our findings demonstrated that montanine significantly attenuated the development of experimental arthritis in both acute and chronic models. In AIA, montanine was able to reduce the leukocyte influx to the joint, which at 24 h after ia injection mainly consists of polymorphonuclear cells (van den Berg et al., 1981) , an important marker of local inflammatory activity (Grespan et al., 2008) and nociception. In CIA, montanine reduced the clinical score of arthritis and prevented histologic damage both when administered in a prophylactic way prior to the onset of arthritis or therapeutically after the onset of disease. Additionally in the therapeutic treatment protocol of CIA, a reduction in paw nociception was observed. In a review of literature, Hegen et al. (Hegen et al., 2008) found that the most approved drugs for treatment of RA have data on therapeutic efficacy from AIA and CIA, indicating that these two models together constitute an important proof-of-concept paradigm for preclinical drug development.
In vitro, montanine reduced lymphocyte proliferation induced by conA, a preferentially mitogen for T-lymphocytes (Hadden et al., 1976) . T cells are importantly involved in RA pathogenesis and are an effective target for disease treatment (Smolen et al., 2012) , as well as their depletion has been reported to delay CIA development (Ranges et al., 1985) . This suppressive effect of montanine on T lymphocytes could be related to the observed in vivo anti-arthritic effect. It has been shown that the Amaryllidaceae alkaloid lycorine acts in vitro on Jurkat cells (a leukemic T lymphocyte cell line) through induction of apoptosis (McNulty et al., 2009; Evidente et al., 2009 ), but the effect of montanine seems to be due a different mechanism, since the concentration used in vitro was not found to increase lymphocyte death. Nonetheless, further studies are needed to better evaluate a possible direct action of montanine on these cells.
FLS has a key role in pannus formation and joint destruction (Bottini and Firestein, 2013) through the ability to invade cartilage and bone. This ability can be tested in vitro using a matrigel-coated transwell system. We observed a reduction on 54% of total number of invading cells on DBA/1 J FLS treated with montanine. The in vitro FLS invasion phenotype correlates with radiologic joint destruction for RA patients (Tolboom et al., 2005) and histological joint damage for rat (Laragione et al., 2008) , indicating that our finding is clinically relevant. Again, more studies are needed to investigate this apparently direct effect of the alkaloid on FLS.
Despite the increase of biological studies with Amaryllidaceae alkaloids, inspired by the clinical use of galantamine in Alzheimer's disease (Nakano et al., 2015) , little is known about their effects on inflammatory conditions. These alkaloids seem to deplete some proinflammatory mediators (Ji et al., 2014; Kang et al., 2012; Satapathy et al., 2011; Pavlov et al., 2009; Liu et al., 2015; Elgorashi and van Staden, 2004) . Specifically in arthritis research, two studies in rat adjuvant-induced arthritis models demonstrated the protective effects of galantamine on disease development by reducing TNF-α, edema and radiological changes (Gowayed et al., 2015) , and of lycoricidinol through suppression of edema (Mikami et al., 1999) .
Previous work has shown that montanine presents psychopharmacological activities in rodents. In open field and elevated plus maze tests, montanine induced a sedative and anxiolytic effect, while in the pentylenotetrazole-induced seizure model the alkaloid showed a dosedependent anticonvulsant activity. Additionally, in the forced swimming test, montanine reduced total immobility time and enhanced struggling behaviour, indicating an antidepressant effect in response to inescapable stress (da Silva et al., 2006) . In an ex vivo analysis of rat hippocampus slices, montanine inhibited in a dose-dependent manner the acetylcholinesterase activity (Pagliosa et al., 2010) . Finally, montanine has been reported to have antiproliferative activity in vitro against human cancer cell lines (Silva et al., 2008) . Nevertheless, our study is the first to evaluate and demonstrate a beneficial effect of montanine in arthritis, with clear protection of cartilage and bone damage.
Regarding the doses used in our experiments, it were chosen based on a previous work (da Silva et al., 2006) . Once AIA is a 24 h model, animals were treated with higher doses of montanine. The doses were decreased in CIA therapeutic model because of the continuous treatment (twice a day for 10 days) and further reduced in the CIA prophylactic model, once mice started to be treated before the effective clinical onset of the disease. A study of acute toxicity indicated a median lethal dose (LD 50 ) value of 64.7 mg/kg of montanine for male mice, and the occurrence of side effects as altered motor activity, decreased respiratory rate, violent body tremors and clonic convulsions (da Silva et al., 2006) . Therefore we evaluated disease modifying antirheumatic activity of montanine in very lower doses, not observing any of those changes.
Interestingly, the higher dose of montanine in clinical protocol of CIA (1.5 mg/kg) showed no effect on arthritis severity and paw nociception. Although a higher dose was used in AIA and presented therapeutic effect (3 mg/kg), it was administered only twice during the experimental procedure, while in the CIA protocol montanine was given in followed administrations for a relative long period. We can hypothesize that the increased availability of molecules of montanine leads to an acute activation that culminates with mechanisms of desensitization of the receptor, reducing the activation of receptor cell signaling and, consequently, decreasing the biological effect seen at lower doses. These data draws attention to the importance of a better understanding of the pharmacokinetics of montanine and further studies should be conducted for optimal therapeutic purpose.
Due to the complexity of autoimmune rheumatic diseases, and based on the growing experience with targeted biologic therapies, blocking a single target is unlikely to provide dramatic efficacy in all patients with RA. This fact demonstrates the importance of the development of molecules that might act on different pathways that are also important to the disease pathogenesis or that are involved in multiple pathways (Mina-Osorio, 2015) . For example, considering the increased risk of infections with all current DMARDs used in RA, molecules with direct effect on FLS, which are critical in joint destruction, and with minor immunosuppressive effects could represent a relevant addition to the treatment of these diseases.
Conclusions
Taken together, our results suggest that montanine has a potential to become a drug to treat arthritis through a combined systemic disease modifying anti-rheumatic activity and a local FLS-aggressiveness regulatory action. Therefore, we believe that additional efforts should be directed to clarify the effect on inflammatory pathways, the molecular mechanisms of action and the pharmacokinetic characteristics of montanine to support future development of clinical trials with this potential new therapy.
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